Breaking Ground In Prevention & Relief Of Anxiety & PTSD: Silo Pharma' Nasal Formulation For Ketamine-Based Treatment

Silo Pharma SILO, a developmental-stage biopharma company merging traditional therapeutics with psychedelic research, has advanced the formulation development for its ketamine-composed drug SPC-15. 

The company aims to combine the liquid nasal formulation and SPC-15’s novel protocol intended for the treatment and prevention of anxiety, PTSD and other stress-related disorders.

Silo Pharma’s U.S. patent, received in May, “Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders” includes claims covering the key tech behind SPC-15 and further drug discovery. 

See Also: Zappy Zapolin's Psycheceutical Files Patent, Hopes Ketamine Topical Can Treat PTSD

The feasibility study assessing SPC-15’s dose strengths is being conducted within the framework of a sponsored research agreement and option with partner Columbia University. To date, it has shown positive linearity, accuracy, and repeatability. 

For CEO Eric Weisblum, the progress of this study constitutes “a significant advancement” in the company’s development work with the pipeline candidate. 

While final results will determine Silo Pharma’s selection of the manufacturing processes, Weisblum says that the company is currently in discussions with potential delivery partners.

Further, the feasibility data could be used for upcoming studies related to the company’s SPC-14 therapeutic targeting Alzheimer’s, which are also being conducted under the research agreement with Columbia.

Yes we cover psychedelics, but we also truly own the expertise in the cannabis world! If you still haven’t heard about our biannual crowd-puller Cannabis Capital Conference, come join us and see for yourself!

This September 27-28, the epicenter of cannabis investment and branding is coming to Chicago. Come get your deals done at our 17th CCC edition. Tickets HERE.

Photo: Benzinga edit with photo by Bacsica, aiyoshi597, Gisele Yashar and Gorodenkoff on Shutterstock.